GMO Group brings together a UK commercial gateway, an Egypt-focused pharmaceutical platform, a global sourcing and tender network, and a Jordan-based health intelligence foundation.
GMO Group is structured to keep capabilities complementary rather than overlapping — combining commercial reach, healthcare supply execution, market development, and evidence-led institutional work under a single international group identity.
Each entity has a defined lane. The result is a coordinated operating model for manufacturers, wholesalers, hospitals, tender authorities, distributors, investors and strategic healthcare partners.
Clear responsibilities allow the group to move from intelligence to sourcing, from commercial structuring to market execution, without blurring mandates between subsidiaries.
International B2B healthcare supply, shortage response, commercial sourcing and market-access coordination connecting UK / Europe suppliers with global buyers.
Egypt-focused pharmaceutical and healthcare commercial development, supporting market entry, portfolio development and regional expansion.
Manufacturer representation, international sourcing, tender development and MENA / Africa market development across pharmaceuticals, devices and healthcare products.
Jordan-based foundation platform for health research, analytical work, stakeholder engagement and evidence-led initiatives that strengthen healthcare decision support.
Use the matrix below to route an opportunity to the entity with the most relevant operating mandate, while preserving group-level coordination where a project spans more than one market.
Product and supplier identification across pharmaceuticals, hospital products, devices, consumables and selected healthcare categories.
Structured response to time-sensitive product requirements, including supplier outreach, documentation coordination and commercial follow-through.
Commercial pathway design, partner identification and market-development support for selected UK, MENA, African and international opportunities.
Opportunity screening, quotation coordination, manufacturer alignment and execution support for institutional procurement.
Commercial representation, portfolio introduction and long-term market-development conversations with regional buyers and partners.
Egypt-focused portfolio strategy and coordination with local stakeholders, with all regulated activities subject to applicable authorization requirements.
Evidence gathering, health-system context and analytical support designed to improve the quality of institutional and commercial decisions.
Cross-border opportunity orchestration where supplier, distributor, tender and market-access capabilities must operate in a coordinated model.
GMO Group works at the intersection of supply continuity, commercial development and healthcare market intelligence — with each entity operating from its defined mandate.
Selected operating markets and client relationships are shown below alongside additional network markets. Geographic presence is project- and partner-dependent.
The group has evolved from a focused healthcare commercial operation into a connected international platform with distinct specialist entities.
Global Medical Offers establishes the group’s healthcare commercial roots, focused on sourcing, market development and manufacturer relationships.
ORBIWAY LIMITED is incorporated in the UK, extending the group’s cross-border commercial and healthcare supply architecture into the British market.
UK, Egypt, Jordan and global commercial capabilities are being structured into a coordinated platform for international healthcare supply and market access.
Expand trusted supplier networks, institutional relationships, market pathways and healthcare product categories while retaining clear entity-level responsibilities.
A visual expression of the environments the group works across: science, healthcare operations, logistics, partnerships and global commerce.
Senior leadership provides group-level direction while each operating entity retains a clear mandate and accountable execution model.
Chief Executive Officer, GMO Group
Chief Executive Officer, Tahleel Foundation
Managing Director, ORBIWAY
For manufacturer representation, shortage response, tender opportunities, market entry, healthcare supply or strategic partnerships, route your enquiry to the relevant GMO Group team.
